Premium
Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population
Author(s) -
Fan Weiwei,
Zhou Keke,
Hu Dezhi,
Song Xiao,
Zhao Yingjie,
Chen Hongyan,
Wei Qingyi,
Chen Gong,
Shi Jinlong,
Du Guhong,
Mao Ying,
Lu Daru,
Zhou Liangfu
Publication year - 2012
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.20842
Subject(s) - biology , single nucleotide polymorphism , haplotype , odds ratio , glioma , genotype , medicine , mmp3 , confidence interval , genetics , oncology , case control study , bioinformatics , gene , gene expression
Matrix metallopeptidases ( MMPs ) play an important role in central nervous system tumor growth, invasion and spreading. The currently available data provide clear evidence for the involvement of MMP3 in the pathophysiology of glioma. The study aims to explore the association of single nucleotide polymorphisms (SNPs) across the MMP3 gene with glioma risk. Three haplotype tagging and additional two promoter SNPs were genotyped among 766 glioma patients and 824 cancer‐free controls from East China. None of these polymorphisms alone had a significant effect on risk of gliomas. However, when three promoter polymorphisms were evaluated together by the number of putative risk of genotypes (i.e., rs645419AA, 632478CA+AA, rs522616AA), a statistically significantly increased risk of gliomas was associated with the combined genotypes with two to three risk genotypes, compared with those with zero to one risk genotypes (adjusted odds ratio (OR) = 1.32; 95% confidence interval (CI) = 1.03–1.68). This increased risk was also more pronounced among adults (adjusted OR = 1.14, 95%CI = 1.02–1.27), males (adjusted OR = 1.19, 95%CI = 1.05–1.36), smokers (adjusted OR = 1.28, 95%CI = 1.07–1.52), subjects with no family history of cancer (adjusted OR = 1.21, 95%CI = 1.07–1.37), and patients with nonastrocytic gliomas (adjusted OR = 1.23, 95%CI = 1.06–1.43). In summary, our results suggest that any one of MMP3 variants may not have a substantial effect on glioma risk, but a joint effect of MMP3 promoter polymorphisms may contribute to risk of gliomas, particularly for adult gliomas. © 2011 Wiley Periodicals, Inc.